Peter Cusworth, account manager for industrial automation company Yokogawa explores the challenges pharmaceutical manufacturers in the UK are facing when it comes to data integrity.
Consumer safety is at the forefront of regulators’ minds when they audit a drug manufacturer’s facility. This is especially true in an industry where the lines between science and technology continue to blur, opening the door to several potential errors and oversights.
Safety is without question the top priority, but checks are also made to ensure consistent and high-quality products. Process errors can be missed if values aren’t monitored across all phases of discovery and development, resulting in sub-par products that not only damage a company’s reputation but may also be unfit for human consumption. Any drug released must adhere to strict regulatory standards and have robustly recorded information to prove results are an accurate reflection of the development process.